Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital and Optimizers group in connection with the acquisition of Vendre
Mandate

Vinge advises Main Capital and Optimizers group in connection with the acquisition of Vendre

January 30, 2023 Employment and Benefits Commercial Agreements Intellectual Property M&A IT, Telecommunications and Outsourcing Data protection and processing of personal data

Vendre is a provider of an innovative module-based eCommerce platform for customers in both B2B and B2C markets

Vendre AB was founded in 2007 and provides an innovative eCommerce platform with several different and unique functionalities to its over one hundred customers. Through the acquisition, Main Capital’s portfolio company Optimizers strengthens its product offering and position in the Nordic market, growing towards EUR 25 million in revenues and 170 employees.

Vinge’s team mainly consisted of Filip Öhrner, Olivia Belding, Nando Basic (M&A), Ebba Svenburg (Employment), Martin Boström (Commercial Agreements) Lisa Hörnqvist (IT and GDPR), Rebecka Målquist, Johan Gavelin (IP) and Ellinore Boström Andersson (project assistant).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025